American Thoracic Society International Conference

Phase 3 TETON-1 data show inhaled treprostinil reduced FVC decline by 130 mL and cut clinical worsening risk 33% in IPF patients over 52 weeks, according to Steven Nathan, MD.

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

5 interviews in 5 minutes. Check out this HCPLive Five at ATS 2026 on late breaking data in sleep apnea, lung function recovery, PAH, lung disease, and COPD.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

At ATS 2026, Krunal Patel, MD, discussed early real-world data suggesting sotatercept may improve hemodynamics, RV remodeling, and functional outcomes in group 3 CLD-PH.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.

A quantitative CT-based approach may help predict pneumothorax risk after bronchoscopic lung volume reduction, according to findings presented at ATS 2026.

ATS 2026 data presented by Jamey Moore, DO, suggest greater upfront corticosteroid dosing may shorten hospitalization in acute exacerbations of autoimmune-related ILD.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.

This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).

At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.

This potential new treatment option shows potential for patients living with obstructive sleep apnea.

Periconception eosinophils may serve as a biomarker to identify asthma risk in gestation, according to Christian Cardillo, MD, who presented late-breaking data at ATS 2026.

In patients with COPD, heart rate measured during the 6-minute walk test were associated with greater hospital utilization, according to Andrew Truong-An Ho, MD, at ATS 2026.

At ATS 2026, Robert Wallis, MD, shared preliminary phase 2c data showing a novel 4-month pan-TB regimen containing sutezolid and N-acetylcysteine improved lung function recovery.

Maintenance extracorporeal photopheresis was associated with improved survival in lung transplant recipients with bronchiolitis obliterans syndrome, according to Alan Betensley, MD.